What is Avalo Therapeutics, Inc.'s earnings per share (EPS)?

Avalo Therapeutics, Inc. (AVTX) reported diluted earnings per share of -$5.84 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Avalo Therapeutics, Inc. (AVTX) Financials

AVTX

FY2025 annual

Revenue $59K -86.6% YoY

Net Income -$78.3M -122.8% YoY

EPS (Diluted) -$5.84 YoY not available

Operating Cash Flow -$51.5M -4.9% YoY

Market Cap $803.9M as of Oct 3, 2026

Price / Sales n/m outside the range published as a multiple, on $59K revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.8x on $448.7M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AVTX SEC filings page.

Avalo Therapeutics, Inc. (AVTX) reported $59K in revenue for fiscal year 2025, down 86.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AVTX FY2025 2026-10-04

Avalo now operates as a development-stage biotech: $50.1M of research spending dwarfs $59K of revenue, leaving financing central.

Revenue fell from $441K in FY2024 to $59K in FY2025 while operating cash outflow worsened, showing that lower activity did not reduce the cash burden. With operating cash flow at -$51.5M and net loss at $78.3M, cash consumption and accounting loss moved together, making current spending—not revenue—the dominant operating mechanism.

FY2025 R&D spending of $50.1M against $59K of revenue means the reported cost base is aimed at developing the business rather than being funded by current sales. This is a development-led operating model, not a revenue-scaled one.

The balance sheet is less liability-heavy than the earnings profile suggests: FY2025 liabilities were $33.4M versus equity of $83.0M, indicating a comparatively equity-funded structure. Reported liquidity equaled 22.9 months of the latest annual operating outflow comparison, which describes funding capacity but not improved earnings.

Financial Health Signals

Financial health score not available

Avalo Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

7.93

Avalo Therapeutics, Inc. scores 7.93, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($803.9M) relative to total liabilities ($33.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Avalo Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Avalo Therapeutics, Inc. reported a net loss of $78.3M while operations used $51.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$31.5M

YoY-64.2%

QoQ-50.8%

Avalo Therapeutics, Inc.'s EBITDA was -$31.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 64.2% from the same quarter a year earlier. Against the prior quarter it is down 50.8%.

Net Income

-$36.4M

YoY-75.1%

QoQ-85.2%

Avalo Therapeutics, Inc. reported -$36.4M in net income in Q2 2026. This represents a decrease of 75.1% from the same quarter a year earlier. Against the prior quarter it is down 85.2%.

EPS (Diluted)

-$0.83

Avalo Therapeutics, Inc. earned -$0.83 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$85.4M

YoY+101.9%

QoQ+241.7%

5Y CAGR+16.1%

10Y CAGR+21.8%

Avalo Therapeutics, Inc. held $85.4M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

54M

5Y CAGR-11.0%

10Y CAGR+20.0%

Avalo Therapeutics, Inc. had 54M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-8.1%

YoY+11.8pp

QoQ+20.6pp

Avalo Therapeutics, Inc.'s ROE was -8.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 11.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 20.6 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$23.4M

YoY+66.4%

QoQ+66.7%

Avalo Therapeutics, Inc. invested $23.4M in research and development in Q2 2026. This represents an increase of 66.4% from the same quarter a year earlier. Against the prior quarter it is up 66.7%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

AVTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVTX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	N/A	$59K-86.6%	$441K-77.1%	$1.9M-89.3%	$18.1M+234.4%	$5.4M-19.4%	$6.7M-0.8%	$6.8M-4.0%	$7.0M-74.7%	$27.8M+2312.3%	$1.2M	$0	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	$1.3M-62.6%	$3.4M+130.3%	$1.5M+397.0%	$300K+153.0%	-$567K-117.4%	$3.3M+413.0%	$636K	$0	$0	N/A	N/A
Gross Profit	N/A	N/A	N/A	$640K-95.6%	$14.6M+274.1%	$3.9M-38.9%	$6.4M	N/A	$3.8M-86.1%	$27.2M+2257.1%	$1.2M	$0	N/A	N/A
R&D Expenses	N/A	$50.1M+105.0%	$24.4M+77.3%	$13.8M-56.0%	$31.3M-47.7%	$59.8M+85.9%	$32.2M+173.7%	$11.8M+103.3%	$5.8M+32.3%	$4.4M-56.9%	$10.1M+54.1%	$6.6M-46.2%	$12.2M+37.3%	$8.9M
SG&A Expenses	N/A	$22.9M+32.8%	$17.2M+67.4%	$10.3M-50.3%	$20.7M-16.0%	$24.7M+41.6%	$17.4M+72.1%	$10.1M-3.7%	$10.5M+32.4%	$7.9M+12.1%	$7.1M+60.2%	$4.4M-9.3%	$4.9M+21.3%	$4.0M
Operating Income	N/A	-$72.9M-6.4%	-$68.5M-150.5%	-$27.4M+26.9%	-$37.4M+54.4%	-$82.1M-12.8%	-$72.8M-351.4%	-$16.1M+54.4%	-$35.4M-354.7%	$13.9M+186.4%	-$16.1M-46.1%	-$11.0M+35.7%	-$17.1M-32.3%	-$12.9M
EBITDA	N/A	-$72.6M-6.2%	-$68.3M-151.3%	-$27.2M+27.0%	-$37.3M+53.7%	-$80.5M-13.3%	-$71.0M-479.4%	-$12.3M+60.2%	-$30.8M-315.3%	$14.3M+189.2%	-$16.1M-46.1%	-$11.0M+35.7%	-$17.1M-32.3%	-$12.9M
Interest Expense	N/A	N/A	N/A	$3.4M-18.1%	$4.2M+74.4%	$2.4M	N/A	N/A	N/A	$24K-94.8%	$464K-41.5%	$793K-34.2%	$1.2M	N/A
Income Tax	N/A	$165K+44.7%	$114K+714.3%	$14K-50.0%	$28K+114.3%	-$196K+93.0%	-$2.8M-1096.4%	$280K+666.7%	-$49K-102.5%	$2.0M	$0	$0	N/A	N/A
Net Income	N/A	-$78.3M-122.8%	-$35.1M-11.4%	-$31.5M+24.3%	-$41.7M+50.6%	-$84.4M-32.9%	-$63.5M-295.1%	-$16.1M+59.9%	-$40.1M-437.4%	$11.9M+172.1%	-$16.5M-57.0%	-$10.5M+34.7%	-$16.1M-23.1%	-$13.0M
EPS (Basic)	N/A	-$5.84+26.4%	-$7.94+93.0%	-$113.58+89.3%	-$1063.00	N/A	N/A	N/A	-$1.20-385.7%	$0.42+122.5%	-$1.87+60.3%	-$4.71	N/A	N/A
EPS (Diluted)	—	-$5.84	-$20.91	-$113.58	-$1063.00	N/A	N/A	N/A	-$1.20-385.7%	$0.42	-$1.87	-$4.71	N/A	N/A
Diluted Shares (Avg)	N/A	13M	7M	277,727	39,202	N/A	N/A	N/A	35M+85.4%	19M	9M	2M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	$0-100.0%	N/A	N/A	N/A	$249K+5.5%
Cost of Revenue	N/A	N/A	N/A	N/A	$0-100.0%	N/A	N/A	-$714K-389.1%
R&D Expenses	$23.4M+66.4%	$14.0M+54.0%	N/A	$13.6M+42.8%	$14.1M+205.9%	$9.1M+331.1%	N/A	$9.5M+663.7%
SG&A Expenses	$8.1M+54.5%	$6.9M+23.6%	N/A	$5.6M+30.1%	$5.2M+15.8%	$5.5M+73.7%	N/A	$4.3M+72.1%
Operating Income	-$31.5M-63.2%	-$20.9M-42.5%	N/A	-$19.2M-49.3%	-$19.3M-101.7%	-$14.7M+55.2%	N/A	-$12.9M-243.0%
EBITDA	-$31.5M-64.2%	-$20.9M-43.7%	N/A	-$19.1M-49.2%	-$19.2M-101.0%	-$14.5M+55.6%	N/A	-$12.8M-245.8%
Income Tax	$18K+12.5%	$12K+50.0%	N/A	$11K+178.6%	$16K+128.6%	$8K+14.3%	N/A	-$14K-275.0%
Net Income	-$36.4M-75.1%	-$19.6M-49.3%	N/A	-$30.6M-232.9%	-$20.8M-121.1%	-$13.1M+89.2%	N/A	$23.0M+540.6%
EPS (Basic)	-$0.83+56.8%	-$0.98+21.6%	-$0.37+95.3%	-$2.19-323.5%	-$1.92-145.6%	-$1.25+99.1%	-$7.95-106.8%	$0.98+3756.7%
EPS (Diluted)	-$0.83	-$0.98	-$0.37	-$2.19+22.6%	-$1.92	-$1.25	$1.72	-$2.83
Diluted Shares (Avg)	44M	20M	N/A	14M+29.8%	11M	11M	N/A	11M

Not reported in any period shown, so not listed: Gross Profit, Interest Expense.

AVTX Balance Sheet

AVTX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$116.5M-22.7%	$150.7M+618.0%	$21.0M-37.1%	$33.4M-58.4%	$80.2M+83.3%	$43.8M+21.2%	$36.1M-48.6%	$70.3M+64.1%	$42.8M+642.0%	$5.8M-73.4%	$21.7M+75.8%	$12.3M	N/A
Current Assets	$105.3M-24.2%	$138.9M+1554.4%	$8.4M-48.9%	$16.4M-73.5%	$61.8M+137.8%	$26.0M+46.7%	$17.7M-19.2%	$21.9M+105.5%	$10.7M+88.5%	$5.7M-73.8%	$21.6M+77.8%	$12.2M	N/A
Cash & Equivalents	$15.9M-88.2%	$134.5M+1714.5%	$7.4M-43.7%	$13.2M-75.9%	$54.6M+188.5%	$18.9M+424.2%	$3.6M-66.1%	$10.6M+330.6%	$2.5M-51.8%	$5.1M-75.8%	$21.2M+80.2%	$11.7M+243.2%	$3.4M
Short-Term Investments	$82.5M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	$0-100.0%	$20K-47.4%	$38K+1166.7%	$3K-85.9%	$21K-93.3%	$318K-16.8%	$382K	$0	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$0-100.0%	$1.1M-51.3%	$2.2M+117.3%	$1.0M+21.8%	$822K-72.0%	$2.9M+2115.6%	$132K	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$10.5M0.0%	$10.5M0.0%	$10.5M-27.1%	$14.4M0.0%	$14.4M0.0%	$14.4M0.0%	$14.4M0.0%	$14.4M+17.2%	$12.3M	$0	N/A	N/A	N/A
Total Liabilities	$33.4M+88.8%	$17.7M+29.3%	$13.7M-69.1%	$44.3M-22.5%	$57.1M+197.7%	$19.2M+27.0%	$15.1M-69.4%	$49.3M+230.1%	$14.9M+168.7%	$5.6M-35.1%	$8.6M-77.8%	$38.6M	N/A
Current Liabilities	$12.9M+85.9%	$7.0M+50.7%	$4.6M-79.1%	$22.1M+11.2%	$19.9M+30.6%	$15.2M+25.2%	$12.2M-53.6%	$26.2M+136.4%	$11.1M+157.2%	$4.3M-26.3%	$5.8M+17.1%	$5.0M	N/A
Non-Current Liabilities	$20.5M+90.6%	$10.7M+18.4%	$9.1M-59.1%	$22.2M-40.5%	$37.2M+838.6%	$4.0M+34.4%	$3.0M-87.2%	$23.1M+499.4%	$3.9M+208.6%	$1.3M-54.1%	$2.7M-91.9%	$33.7M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$14.3M	$0	$0-100.0%	$2.4M-55.7%	$5.3M	N/A
Total Equity	$83.0M-37.6%	$133.0M+1721.4%	$7.3M+166.9%	-$10.9M-147.3%	$23.1M-6.0%	$24.6M+17.0%	$21.0M+0.4%	$20.9M-25.0%	$27.9M+13358.6%	$207K-98.4%	$13.1M+149.7%	-$26.3M-47.5%	-$17.8M
Retained Earnings	-$448.5M-21.1%	-$370.3M-10.5%	-$335.1M-10.3%	-$303.8M-15.9%	-$262.2M-47.5%	-$177.8M-55.6%	-$114.3M-16.4%	-$98.2M-68.9%	-$58.2M+16.9%	-$70.0M-30.8%	-$53.6M-24.4%	-$43.1M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$490.8M+287.7%	$99.9M-27.9%	$116.5M-22.7%	$125.1M+27.1%	$126.6M+16.9%	$138.5M+12.0%	$150.7M+618.0%	$98.5M+236.4%
Current Assets	$407.9M+254.2%	$88.8M-30.0%	$105.3M-24.2%	$113.8M+32.2%	$115.2M+20.1%	$126.9M+14.1%	$138.9M+1554.4%	$86.1M+580.5%
Cash & Equivalents	$85.4M+101.9%	$25.0M-80.0%	$15.9M-88.2%	$27.0M-67.1%	$42.3M-54.7%	$125.0M+13.5%	$134.5M+1714.5%	$81.9M+704.1%
Short-Term Investments	$314.9M+343.7%	$57.0M	$82.5M	$84.7M	$71.0M	$0	$0	$0
Long-Term Investments	$71.9M	$0	$0	$0	$0	$0	$0	$0
Goodwill	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M-27.1%
Total Liabilities	$42.1M+91.4%	$31.6M+98.4%	$33.4M+88.8%	$33.6M-55.7%	$22.0M-80.1%	$15.9M-92.9%	$17.7M+29.3%	$75.7M+419.5%
Current Liabilities	$21.1M+128.2%	$11.6M+106.6%	$12.9M+85.9%	$8.0M-86.9%	$9.3M-90.4%	$5.6M-97.4%	$7.0M+50.7%	$60.7M+910.4%
Non-Current Liabilities	$21.0M+64.7%	$20.0M+94.0%	$20.5M+90.6%	$25.6M+70.0%	$12.8M-9.3%	$10.3M+12.9%	$10.7M+18.4%	$15.0M+75.6%
Total Equity	$448.7M+329.0%	$68.3M-44.3%	$83.0M-37.6%	$91.5M+334.4%	$104.6M+868.5%	$122.6M+209.0%	$133.0M+1721.4%	$21.1M+43.4%
Retained Earnings	-$504.5M-24.8%	-$468.2M-22.1%	-$448.5M-21.1%	-$434.8M-29.8%	-$404.2M-12.9%	-$383.4M+16.0%	-$370.3M-10.5%	-$334.9M-2.4%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

AVTX Cash Flow Statement

AVTX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$68.3M	-$51.5M-4.9%	-$49.1M-59.9%	-$30.7M-14.7%	-$26.8M+62.3%	-$70.9M-74.9%	-$40.5M-111.9%	-$19.1M-511.7%	-$3.1M-124.9%	$12.6M+186.3%	-$14.6M-43.4%	-$10.2M+34.5%	-$15.5M-35.1%	-$11.5M
Depreciation & Amortization	N/A	$344K+103.6%	$169K+7.0%	$158K-4.8%	$166K-90.0%	$1.7M-10.1%	$1.8M-52.5%	$3.9M-14.7%	$4.6M+970.6%	$425K+1484.3%	$27K+14.2%	$24K-18.8%	$29K+44.5%	$20K
Stock-Based Compensation	N/A	$13.6M+132.8%	$5.9M+68.3%	$3.5M-54.0%	$7.6M-7.6%	$8.2M+20.4%	$6.8M+168.0%	$2.5M+4.2%	$2.4M+110.1%	$1.2M-31.7%	$1.7M+329.4%	$395K-63.7%	$1.1M+45.1%	$749K
Capital Expenditures	N/A	N/A	N/A	N/A	$95K-15.9%	$113K+79.4%	$63K-76.0%	$262K-53.6%	$564K+2319.8%	$23K-33.1%	$35K+74.6%	$20K+2.5%	$20K-33.4%	$29K
Free Cash Flow	N/A	N/A	N/A	N/A	-$26.8M+62.2%	-$71.0M-74.9%	-$40.6M-109.3%	-$19.4M-425.3%	-$3.7M-129.4%	$12.6M+185.9%	-$14.6M-43.4%	-$10.2M+34.5%	-$15.5M-34.9%	-$11.5M
Investing Cash Flow	-$315.3M	-$81.7M-23055.1%	$356K+367.7%	-$133K-40.0%	-$95K+15.9%	-$113K-101.0%	$11.1M+2612.9%	-$443K-151.2%	$865K+104.6%	-$18.9M-54116.3%	-$35K-74.6%	-$20K	N/A	N/A
Financing Cash Flow	$426.7M	$14.6M-91.7%	$175.8M+602.2%	$25.0M+270.4%	-$14.7M-113.8%	$106.8M+138.4%	$44.8M+256.6%	$12.6M+20.7%	$10.4M+178.4%	$3.7M+362.1%	-$1.4M-107.3%	$19.6M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$20.0M-75.5%	-$17.7M-87.1%	-$14.2M+5.3%	-$16.4M-42.0%	-$11.4M+30.0%	-$9.5M-52.5%	-$15.0M-443.9%	-$11.5M-68.6%
Depreciation & Amortization	$17K-87.3%	$17K-87.4%	$16K-76.5%	$59K+73.5%	$134K+306.1%	$135K+297.1%	$68K+58.1%	$34K-17.1%
Stock-Based Compensation	$5.3M+95.2%	$3.6M+10.3%	N/A	$3.2M+70.6%	$2.7M+477.1%	$3.2M+415.3%	N/A	$1.8M+93.9%
Investing Cash Flow	-$329.9M-365.6%	$25.5M	$2.4M	-$13.3M	-$70.9M	$0-100.0%	$0	$0
Financing Cash Flow	$410.2M+87564.6%	$1.4M	$687K-99.0%	$14.4M	-$469K+0.6%	$0-100.0%	$67.7M+6770800.0%	$0-100.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

AVTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVTX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Gross Margin	N/A	N/A	33.3%-47.7pp	81.0%+8.6pp	72.4%-23.1pp	95.5%	N/A	53.6%-44.1pp	97.7%-2.3pp	100.0%	N/A	N/A	N/A
Operating Margin	-123601.7%	-15535.6%	-1421.6%	-207.4%	-1521.6%	-1087.4%	-239.1%	-503.4%	49.9%	-1394.6%	N/A	N/A	N/A
Net Margin	-132642.4%	-7965.8%	-1639.5%	-230.8%	-1563.1%	-947.9%	-238.1%	-569.9%	42.7%	-1428.6%	N/A	N/A	N/A
Return on Equity	-94.2%-67.8pp	-26.4%+405.5pp	-431.9%	N/A	-365.6%-107.0pp	-258.5%-182.0pp	-76.5%+115.0pp	-191.6%-234.2pp	42.6%+7999.8pp	-7957.2%-7877.0pp	-80.2%	N/A	N/A
Return on Assets	-67.2%-43.9pp	-23.3%+126.9pp	-150.3%-25.4pp	-124.8%-19.7pp	-105.2%+39.9pp	-145.1%-100.6pp	-44.5%+12.5pp	-57.0%-84.7pp	27.7%+313.3pp	-285.5%-237.1pp	-48.4%+81.9pp	-130.4%	N/A
Current Ratio	8.14-11.8x	19.96+18.1x	1.82+1.1x	0.74-2.4x	3.11+1.4x	1.71+0.3x	1.46+0.6x	0.84-0.1x	0.96-0.4x	1.31-2.4x	3.70+1.3x	2.44	N/A
Debt-to-Equity	0.40+0.3x	0.13-1.7x	1.87	N/A	2.48+1.7x	0.78+0.1x	0.720.0x	0.69+0.7x	0.000.0x	0.00-0.2x	0.18	N/A	N/A
Asset Turnover	0.000.0x	0.00-0.1x	0.09-0.4x	0.54+0.5x	0.07-0.1x	0.150.0x	0.19+0.1x	0.10-0.5x	0.65+0.4x	0.20+0.2x	0.00	N/A	N/A
FCF Margin	N/A	N/A	N/A	-148.7%	-1315.4%	-606.1%	-287.3%	-52.5%-97.7pp	45.1%	-1267.0%	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-5165.1%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9251.8%
Return on Equity	-8.1%+11.8pp	-28.7%-18.0pp	N/A	-33.5%-142.8pp	-19.9%	-10.7%	N/A	109.3%+144.9pp
Return on Assets	-7.4%+9.0pp	-19.7%-10.2pp	N/A	-24.5%-47.9pp	-16.4%-107.3pp	-9.5%+88.5pp	N/A	23.4%+41.3pp
Current Ratio	19.31+6.9x	7.66-14.9x	8.14-11.8x	14.28+12.9x	12.44+11.4x	22.61+22.1x	19.96+18.1x	1.42-0.7x
Debt-to-Equity	0.09-0.1x	0.46+0.3x	0.40+0.3x	0.37-3.2x	0.21	0.13	0.13-1.7x	3.59+2.6x
Asset Turnover	N/A	N/A	N/A	0.000.0x	N/A	N/A	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Avalo Therapeutics, Inc. AVTX	FY2025	$59K	-$78.3M	N/A	$803.9M	—
Zura Bio Limited ZURA	FY2025	N/A	-$68.7M	N/A	$393.9M	—
Greenwich LifeSciences, Inc. GLSI	FY2025	N/A	-$19.4M	N/A	$249.2M	—
Agenus Inc. AGEN	FY2025	$114.2M	-$3.1M	-2.7%	$377.6M	47/100
Actuate Therapeutics, Inc. ACTU	FY2025	N/A	-$22.2M	N/A	$19.7M	—

Where Avalo Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Avalo Therapeutics, Inc.'s annual revenue?

Avalo Therapeutics, Inc. (AVTX) reported $59K in total revenue for fiscal year 2025. This represents a -86.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Avalo Therapeutics, Inc.'s revenue growing?

Avalo Therapeutics, Inc. (AVTX) revenue declined by 86.6% year-over-year, from $441K to $59K in fiscal year 2025.

Is Avalo Therapeutics, Inc. profitable?

No, Avalo Therapeutics, Inc. (AVTX) reported a net income of -$78.3M in fiscal year 2025.

What is Avalo Therapeutics, Inc.'s EBITDA?

Avalo Therapeutics, Inc. (AVTX) had EBITDA of -$72.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Avalo Therapeutics, Inc.'s return on equity (ROE)?

Avalo Therapeutics, Inc. (AVTX) has a return on equity of -94.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Avalo Therapeutics, Inc.'s operating cash flow?

Avalo Therapeutics, Inc. (AVTX) recorded an outflow of $51.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Avalo Therapeutics, Inc.'s total assets?

Avalo Therapeutics, Inc. (AVTX) had $116.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Avalo Therapeutics, Inc. spend on research and development?

Avalo Therapeutics, Inc. (AVTX) invested $50.1M in research and development during fiscal year 2025.

How many shares does Avalo Therapeutics, Inc. have outstanding?

Avalo Therapeutics, Inc. (AVTX) had 23M shares outstanding as of fiscal year 2025.

What is Avalo Therapeutics, Inc.'s current ratio?

Avalo Therapeutics, Inc. (AVTX) had a current ratio of 8.14 as of fiscal year 2025, which is generally considered healthy.

What is Avalo Therapeutics, Inc.'s debt-to-equity ratio?

Avalo Therapeutics, Inc. (AVTX) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Avalo Therapeutics, Inc.'s return on assets (ROA)?

Avalo Therapeutics, Inc. (AVTX) had a return on assets of -67.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Avalo Therapeutics, Inc.'s P/E ratio?

Avalo Therapeutics, Inc. (AVTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $803.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Avalo Therapeutics, Inc.'s price-to-sales ratio?

Avalo Therapeutics, Inc. (AVTX) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $59K revenue, FY2025). The market capitalization is $803.9M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Avalo Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Avalo Therapeutics, Inc. (AVTX) held $98.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $51.5M over that year. Dividing the one by the other, the reported balance equals about 23 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Avalo Therapeutics, Inc.'s Altman Z-Score?

Avalo Therapeutics, Inc. (AVTX) has an Altman Z-Score of 7.93, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Avalo Therapeutics, Inc.'s Piotroski F-Score?

Avalo Therapeutics, Inc. (AVTX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Avalo Therapeutics, Inc.'s earnings high quality?

Avalo Therapeutics, Inc. (AVTX) reported a net loss of $78.3M while operations used $51.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.